Overview

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Status:
Completed

Trial end date:
2018-10-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, based on prostate-specific antigen (PSA) progression, of abiraterone acetate in participants with metastatic (spread of cancer cells from one part of the body to another) castration (any action, surgical, chemical, or otherwise, by which a male loses the functions of the testes) resistant prostate cancer (cancer in prostrate; a gland that makes fluid that aids movement of sperm) (mCRPC), chemo-naive (treatment of cancer is not done using drugs), who received a prior diethylstilbestrol therapy (DES).

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Abiraterone Acetate
Androgens
Diethylstilbestrol
Fosfestrol
Prednisone